Amgen Inc. (TSX:AMGN)
Canada · Delayed Price · Currency is CAD | Market Cap | 262.71B +30.2% |
| Revenue (ttm) | 51.95B +9.1% |
| Net Income | 10.89B +31.5% |
| EPS | 20.06 +31.3% |
| Shares Out | n/a |
| PE Ratio | 24.13 |
| Forward PE | 15.36 |
| Dividend | 0.73 (2.75%) |
| Ex-Dividend Date | May 15, 2026 |
| Volume | 716 |
| Open | 26.00 |
| Previous Close | 25.75 |
| Day's Range | 26.00 - 26.50 |
| 52-Week Range | 23.95 - 29.21 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 4, 2026 |
About Amgen
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascul... [Read more]
Financial Performance
In 2025, Amgen's revenue was $36.75 billion, an increase of 9.95% compared to the previous year's $33.42 billion. Earnings were $7.71 billion, an increase of 88.53%.
Financial numbers in USD Financial StatementsNews
Amgen announces data at ADA Scientific Sessions on cardiometabolic conditions
Amgen (AMGN) announced new data at the American Diabetes Association, ADA, 86th Scientific Sessions reinforcing its commitment to addressing unmet needs for people living with cardiometabolic conditio...
AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS
VESALIUS-CV Subgroup Results Show Repatha ® Reduces Risk of First Major Cardiovascular Events by 29% in People Living with High-Risk Diabetes New Real-World Data Highlight Treatment Gaps in Current Ob...
Amgen price target lowered to $389 from $425 at Goldman Sachs
Goldman Sachs lowered the firm’s price target on Amgen (AMGN) to $389 from $425 and keeps a Buy rating on the shares. The firm is adjusting its model as the…
AMGEN TO PRESENT AT THE GOLDMAN SACHS 47TH ANNUAL GLOBAL HEALTHCARE CONFERENCE
THOUSAND OAKS, Calif., June 4, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Goldman Sachs 47th Annual Global Healthcare Conference at 9:20 a.m.
Amgen Transcript: Jefferies Global Healthcare Conference 2026
Strong Q1 growth was driven by key products and robust pipeline progress, especially in obesity and oncology. AI is being leveraged across R&D, manufacturing, and commercial operations to boost efficiency and top-line growth. Ongoing tax disputes and continued investment in Puerto Rico manufacturing were discussed.
AMGEN TO PRESENT NEW DATA ACROSS RARE AUTOIMMUNE AND INFLAMMATORY DISEASES AT EULAR 2026
New Phase 3 MITIGATE Open-Label Extension Data Support the Long-Term Safety Profile and Sustained Results of UPLIZNA ® in IgG4-RD Real-World Evidence Supports TAVNEOS ® Efficacy and Safety Profile wit...
European Commission approves Amgen’s Imdylltra for ES-SCLC
Amgen (AMGN) announced that the European Commission has granted marketing authorization for Imdylltra as a monotherapy to treat adults with extensive-stage small cell lung cancer who require systemic ...
AMGEN TO PRESENT AT JEFFERIES GLOBAL HEALTHCARE CONFERENCE
THOUSAND OAKS, Calif., May 29, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at Jefferies Global Healthcare Conference at 9:55 a.m.
This Boring Income Portfolio Strategy Could Unlock 300%+ Upside
Most people think you can't time the market. That's nonsense.
Ember LifeSciences announces new strategic investments boosting Series A to $27M
LOS ANGELES, May 27, 2026 /PRNewswire/ -- Ember LifeSciences, Inc., ("Ember") a leading provider of revolutionary cold chain technology, today announced strategic investments from Amgen Ventures, the ...
Doctors in Japan can again prescribe an Amgen rare-disease drug to new patients, reversing a recommendation made only days ago following 20 deaths
The Japanese drugmaker that sells rare-disease medicine Tavneos said new patients will be able to get the drug, which carries risk of liver injury.
Amgen says CFO Peter Griffith to retire, names Dittrich as successor
Amgen said on Tuesday its chief financial officer, Peter Griffith, would retire, with Thomas Dittrich taking over the role in September.
Amgen CFO Peter Griffith to retire, Thomas Dittrich to succeed
Amgen (AMGN) announced the retirement of Peter Griffith, who has served as the company’s executive vice president and CFO since 2020. The company also announced that Thomas Dittrich will return…
AMGEN ANNOUNCES RETIREMENT OF CHIEF FINANCIAL OFFICER PETER GRIFFITH
Thomas Dittrich Returning to Amgen as CFO THOUSAND OAKS, Calif., May 19, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the retirement of Peter Griffith, who has served as the company's exec...
Amgen's rare disease drug linked to deaths, liver injuries in Japan, WSJ reports
At least 20 people in Japan who took Amgen's rare disease drug have died, while 22 others developed potentially fatal liver injuries, the Wall Street Journal reported on Friday, citing p...
Twenty people in Japan who took an Amgen rare immune-disease drug have died, according to the company that sells the medicine in Japan. U.S. drug regulators had asked Amgen to voluntarily withdraw the drug.
Kissei Pharmaceutical, which sells the rare immune-disease drug in Japan, warned doctors to stop prescribing it to new patients.
Amgen price target lowered to $427 from $432 at Piper Sandler
Piper Sandler lowered the firm’s price target on Amgen (AMGN) to $427 from $432 and keeps an Overweight rating on the shares. Looking at the business from a high level,…
Amgen Transcript: Bank of America Global Healthcare Conference 2026
Strong Q1 growth was driven by key products and robust commercial execution, with Repatha and UPLIZNA showing significant momentum. The pipeline is advancing, notably with MariTide and olpasiran, while the company continues to invest in manufacturing and navigate ongoing IRS matters.
AMGEN TO PRESENT AT THE BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE
THOUSAND OAKS, Calif., May 7, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch Global Healthcare Conference at 10:00 a.m.
Amgen upgraded to Buy from Hold at Freedom Broker
Freedom Broker upgraded Amgen (AMGN) to Buy from Hold with an unchanged price target of $375. Amgen’s Q1 results were “fully in line with our expectations, although the quarter is…
Amgen downgraded to Hold from Buy at Erste Group
Erste Group analyst Hans Engel downgraded Amgen (AMGN) to Hold from Buy.
Erste downgrades Amgen on declining sales growth
Erste Group analyst Hans Engel downgraded Amgen (AMGN) to Hold from Buy, saying the company’s sales growth will likely decline in 2026 and 2027. Amgen’s growth is lower than competitors,…
Amgen to invest additional $300M in U.S. manufacturing network
Amgen (AMGN) announced plans to invest an additional $300M in its U.S. manufacturing network to further advance U.S.-based production capacity, enhance next-generation technologies and support a relia...
Amgen to invest additional $300 million to boost US manufacturing footprint
Amgen said on Monday it was investing an additional $300 million in Puerto Rico to expand its U.S. manufacturing network.
AMGEN ANNOUNCES ADDITIONAL $300 MILLION U.S. MANUFACTURING INVESTMENT, TOTALING NEARLY $2 BILLION OVER THE LAST YEAR
Investment Strengthens American Manufacturing, Supply Chain Resilience and Next-Generation Technology THOUSAND OAKS, Calif., May 4, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced plans to i...